Cangrelor Injection, Powder, Lyophilized, For Solution
Product Images NDC 68083-412

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Cangrelor (NDC 68083-412). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gland Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cangrelor-spl-carton-label (Cangrelor Spl Carton Label)

This text provides information about a medical product called Cangrelor for Injection. It elaborates on the dosage, storage, reconstitution process, manufacturer details, and packing specifications. The product is intended for intravenous use and must be reconstituted and diluted before administration. It includes details such as the amount of cangrelor per vial, the composition, and the reconstitution process. It also mentions the specific conditions for storage and instructions for use.*

FDA Label Image

Cangrelor-spl-container-label (Cangrelor Spl Container Label)

FDA Label Image

Cangrelor-spl-figure-1 (Cangrelor Spl Figure 1)

FDA Label Image

Cangrelor-spl-figure-2 (Cangrelor Spl Figure 2)

This is the chart showing the Pharmacodynamic (PD) characteristics of Cangrelor over time when administered at an infusion rate of 4 meg/kg/min. The chart displays the effects of Cangrelor on various parameters such as recovery time, platelet aggregation, and other factors over a 160-minute period. The data points present information on how Cangrelor influences these characteristics throughout the duration of the infusion.*

FDA Label Image

Cangrelor-spl-figure-3 (Cangrelor Spl Figure 3)

This text provides information about the inhibition of ADP-induced platelet aggregation by cangrelor based on a study using light transmission aggregometry. It includes details of the dosages administered and the measurement of platelet aggregation after cangrelor infusion. The text mentions transitioning to other oral P2Y12 platelet inhibitors after the infusion.*

FDA Label Image

Cangrelor-spl-figure-4 (Cangrelor Spl Figure 4)

FDA Label Image

Cangrelor-spl-structure (Cangrelor Spl Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.